Galenea is an emerging biotechnology company dedicated to enhancing lives through the discovery of novel therapies for central nervous system diseases. Founded in 2003 based upon technology developed at MIT and The Rockefeller University, Galenea is initially focusing on utilizing these proprietary technologies to generate calcineurin-related treatments for schizophrenia.

In July 2006, Galenea moved to a custom-designed facility at 300 Technology Square in Cambridge, MA.